14 / 31
Overall Survival with Durvalumab versus Placebo after
Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC
*Median duration of follow-up for OS was 25.2 months (range 0.2–43.1)
†
Adjusted for interim analysis
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Probability of Overall Survival
3
6
9
12 15 18 21 24 27 30 33 36
45
39 42
Time from Randomization (months)
No. at Risk
Durvalumab
476
464 431 415 385 364 343 319 274 210 115
57
23
2
0
0
Placebo
237
220 198 178 170 155 141 130 117
78
42
21
9
3
1
0
OS HR = 0.68
99.73% CI, 0.469–0.997
†
P=0.00251
75.3%
66.3%
83.1%
55.6%
No. events /
No. patients
(%)
Median OS
(95% CI)
months
Durvalumab 183/476
(38.4)
NR (34.7–NR)
Placebo
116/237
(48.9)
28.7 (22.9–
NR)
0
NR, not reached